



ALEMBIC PHARMACEUTICALS LIMITED  
Regd. Office: Alembic Road, Vadodara 390 003

**AUDITED FINANCIAL RESULTS**

FOR THE YEAR ENDED 31ST MARCH, 2012

₹ in lacs

Particulars	CONSOLIDATED				
	Quarter Ended on 31 st March 2012	Quarter Ended on 31 st December 2011	Quarter Ended on 31 st March 2011	Year Ended on 31 st March 2012	Year Ended on 31 st March 2011
	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
<b>PART- I</b>					
<b>1 (a) Net Sales / Income from Operations</b>					
Domestic	20,373	21,720	18,956	87,718	78,805
Exports	13,857	16,562	10,817	59,071	41,859
Total	34,230	38,282	29,773	146,789	120,664
Less : Excise Duty	151	149	126	554	766
Net Sales / Income from Operations	34,079	38,133	29,647	146,235	119,898
<b>(b) Other Operating Income</b>	182	79	85	404	306
<b>Total Income from Operations</b>	<b>34,261</b>	<b>38,212</b>	<b>29,732</b>	<b>146,639</b>	<b>120,204</b>
<b>2 Expenses</b>					
(a) Decrease/(increase) in stock in trade and work in progress	(3,435)	250	1,613	(6,444)	(472)
(b) Consumption of Raw Materials & Packing Materials	12,684	12,916	10,793	52,824	43,494
(c) Purchase of traded goods	6,055	5,774	2,594	24,412	16,018
(d) Employees' Cost	4,311	4,324	4,181	16,846	14,921
(e) Research and Development Expense	2,214	976	1,574	5,858	4,714
(f) Excise Duty	311	(37)	129	509	664
(g) Other Expenditure	8,011	7,161	6,128	30,593	24,840
<b>Total Expenses</b>	<b>30,149</b>	<b>31,364</b>	<b>27,012</b>	<b>124,597</b>	<b>104,179</b>
<b>3 Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>4,111</b>	<b>6,848</b>	<b>2,720</b>	<b>22,041</b>	<b>16,025</b>
<b>4 Other Income</b>	<b>13</b>	<b>13</b>	<b>3</b>	<b>44</b>	<b>8</b>
<b>5 Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>4,125</b>	<b>6,861</b>	<b>2,723</b>	<b>22,086</b>	<b>16,033</b>
<b>6 Depreciation</b>	<b>892</b>	<b>809</b>	<b>784</b>	<b>3,365</b>	<b>2,959</b>
<b>7 Interest (Net)</b>	<b>538</b>	<b>698</b>	<b>636</b>	<b>2,621</b>	<b>2,389</b>
<b>8 Net Profit / (Loss) from Ordinary Activities before Tax</b>	<b>2,694</b>	<b>5,354</b>	<b>1,303</b>	<b>16,099</b>	<b>10,685</b>
<b>9 Tax Expense</b>					
Less : Provision for Current Tax	526	964	51	3,123	1,864
(Less)/Add : Provision for Deferred Tax (Liability)/Assets	137	(33)	224	(38)	282
<b>10 Net Profit / (Loss) from Ordinary Activities after Tax</b>	<b>2,031</b>	<b>4,423</b>	<b>1,028</b>	<b>13,014</b>	<b>8,539</b>
<b>11 Paid up Equity Share Capital</b> ( Face value of share ₹ 2/- )	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>	<b>3,770</b>
<b>12 Reserves excluding Revaluation Reserve</b>				<b>35,730</b>	<b>25,903</b>
<b>13 Debenture Redemption Reserve</b>				<b>3,125</b>	<b>2,333</b>
<b>14 Basic &amp; Diluted EPS (Not Annualised)</b>	<b>1.08</b>	<b>2.35</b>	<b>0.55</b>	<b>6.90</b>	<b>4.53</b>
<b>15 Debt Equity Ratio</b>	-	-	-	<b>0.94</b>	<b>1.25</b>
<b>16 Debt Service Coverage Ratio</b>	-	-	-	<b>3.06</b>	<b>2.26</b>
<b>17 Interest Service Coverage Ratio</b>	-	-	-	<b>12.40</b>	<b>9.41</b>
<b>PART- II</b>					
<b>A Particulars of Shareholding</b>					
<b>1 Public Shareholding</b>					
- Number of Shares	48763089	48763089	48763089	48763089	48763089
- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
<b>2 Promoters and Promoter Group Shareholding</b>					
- Fully Non - Encumbered					
- Number of Shares	139752825	139752825	139752825	139752825	139752825
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
<b>B INVESTOR COMPLAINTS</b>	<b>Quarter ended on 31st March, 2012</b>				
Pending at the beginning of the quarter	NIL				
Received during the quarter	2				
Disposed of during the quarter	2				
Remaining unresolved at the end of the quarter	NIL				

**Notes :**

- 1 The above results, which includes audited results of the Subsidiary, have been duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website [www.alembic-india.com](http://www.alembic-india.com).
- 2 The Board has recommended dividend on Equity Shares at ₹ 1.40 per share i.e. 70% for the year ended on 31.03.2012 (PY ₹ 1/- per share i.e 50%)
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

**For Alembic Pharmaceuticals Limited**

Place : Vadodara  
Date : 25th April, 2012

**Chirayu Amin**  
**Chairman and Managing Director**

**Visit us at [www.alembic-india.com](http://www.alembic-india.com)**

Alembic Pharmaceuticals Limited

Consolidated Statement of Assets and Liabilities

₹ in lacs

Particulars		As at 31st March, 2012	As at 31st March, 2011
<b>A EQUITY AND LIABILITIES</b>			
<b>1 Shareholders' funds</b>			
	(a) Share capital	3,770.32	3,770.32
	(b) Reserves and surplus	35,729.52	25,903.14
	<b>Sub-total - Shareholders' funds</b>	<b>39,499.84</b>	<b>29,673.46</b>
<b>2 Non-current liabilities</b>			
	(a) Long-term borrowings	9,485.67	12,848.37
	(b) Deferred tax liabilities (net)	952.90	537.46
	(c) Other long-term liabilities	1,229.07	1,184.17
	(d) Long-term provisions	539.04	510.16
	<b>Sub-total - Non-current liabilities</b>	<b>12,206.69</b>	<b>15,080.16</b>
<b>3 Current liabilities</b>			
	(a) Short-term borrowings	13,945.77	14,627.68
	(b) Trade payables	20,914.53	13,856.70
	(c) Other current liabilities	15,057.24	8,490.05
	(d) Short-term provisions	3,566.34	2,636.76
	<b>Sub-total - Current liabilities</b>	<b>53,483.88</b>	<b>39,611.20</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>		<b>105,190.41</b>	<b>84,364.82</b>
<b>B ASSETS</b>			
<b>1 Non-current assets</b>			
	(a) Fixed assets	32,606.16	29,849.57
	(b) Non-current investments	329.99	326.17
	(c) Long-term loans and advances	3,499.13	654.47
	<b>Sub-total - Non-current assets</b>	<b>36,435.28</b>	<b>30,830.21</b>
<b>2 Current assets</b>			
	(a) Inventories	25,874.15	21,923.19
	(b) Trade receivables	19,933.11	20,197.39
	(c) Cash and Bank Balance	4,708.05	628.93
	(d) Short-term loans and advances	18,239.82	10,785.10
	<b>Sub-total - Current assets</b>	<b>68,755.13</b>	<b>53,534.60</b>
<b>TOTAL - ASSETS</b>		<b>105,190.41</b>	<b>84,364.82</b>

For Alembic Pharmaceuticals Limited

Chirayu Amin  
Chairman and Managing Director

₹ in lacs

	Particulars	STANDALONE				
		Quarter Ended on 31 st March 2012	Quarter Ended on 31 st December 2011	Quarter Ended on 31 st March 2011	Year Ended on 31 st March 2012	Year Ended on 31 st March 2011
	<b>PART- I</b>	(Audited)	(Reviewed)	(Audited)	(Audited)	(Audited)
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>					
	Domestic	20,373	21,720	18,956	87,718	78,805
	Exports	11,454	13,340	10,817	49,961	38,147
	Total	31,827	35,060	29,773	137,679	116,952
	Less : Excise Duty	151	149	126	554	766
	Net Sales / Income from Operations	31,676	34,911	29,647	137,125	116,186
	<b>(b) Other Operating Income</b>	182	79	85	404	306
	<b>Total Income from Operations</b>	<b>31,857</b>	<b>34,990</b>	<b>29,732</b>	<b>137,528</b>	<b>116,492</b>
<b>2</b>	<b>Expenses</b>					
	(a) Decrease/(Increase) in stock in trade and work in progress	(3,435)	250	1,613	(6,444)	(472)
	(b) Consumption of Raw Materials & Packing Materials	12,684	12,916	10,793	52,824	43,494
	(c) Purchase of traded goods	4,110	3,272	2,594	16,779	12,857
	(d) Employees' Cost	4,311	4,324	4,181	16,846	14,921
	(e) Research and Development Expense	2,214	976	1,574	5,858	4,714
	(f) Excise Duty	311	(37)	129	509	664
	(g) Other Expenditure	7,712	7,263	6,232	30,200	24,740
	<b>Total Expenses</b>	<b>27,906</b>	<b>28,964</b>	<b>27,117</b>	<b>116,571</b>	<b>100,919</b>
<b>3</b>	<b>Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>3,951</b>	<b>6,026</b>	<b>2,615</b>	<b>20,957</b>	<b>15,573</b>
<b>4</b>	<b>Other Income</b>	<b>13</b>	<b>13</b>	<b>3</b>	<b>44</b>	<b>8</b>
<b>5</b>	<b>Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>3,964</b>	<b>6,039</b>	<b>2,618</b>	<b>21,001</b>	<b>15,581</b>
<b>6</b>	Depreciation	892	809	784	3,365	2,959
<b>7</b>	Interest (Net)	538	698	636	2,621	2,389
<b>8</b>	<b>Net Profit / (Loss) from Ordinary Activities before Tax</b>	<b>2,534</b>	<b>4,532</b>	<b>1,198</b>	<b>15,015</b>	<b>10,233</b>
<b>9</b>	<b>Tax Expense</b>					
	Less : Provision for Current Tax	508	864	23	3,000	1,801
	(Less)/Add : Provision for Deferred Tax (Liability)/Assets	137	(33)	224	(38)	282
<b>10</b>	<b>Net Profit / (Loss) from Ordinary Activities after Tax</b>	<b>1,890</b>	<b>3,701</b>	<b>951</b>	<b>12,054</b>	<b>8,150</b>
<b>11</b>	Paid up Equity Share Capital ( Face value of share ₹ 2/- )	3,770	3,770	3,770	3,770	3,770
<b>12</b>	Reserves excluding Revaluation Reserve				32,316	23,851
<b>13</b>	Debenture Redemption Reserve				3,125	2,333
<b>14</b>	Basic & Diluted EPS (Not Annualised)	1.00	1.96	0.50	6.39	4.32
<b>15</b>	Debt Equity Ratio	-	-	-	1.02	1.34
<b>16</b>	Debt Service Coverage Ratio	-	-	-	2.91	2.20
<b>17</b>	Interest Service Coverage Ratio	-	-	-	11.76	9.13
	<b>PART- II</b>					
<b>A</b>	<b>Particulars of Shareholding</b>					
<b>1</b>	<b>Public Shareholding</b>					
	- Number of Shares	48763089	48763089	48763089	48763089	48763089
	- Percentage of Shareholding	25.87	25.87	25.87	25.87	25.87
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>					
	- Fully Non - Encumbered					
	- Number of Shares	139752825	139752825	139752825	139752825	139752825
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13	74.13
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	<b>Quarter ended on 31st March, 2012</b>				
	Pending at the beginning of the quarter	NIL				
	Received during the quarter	2				
	Disposed of during the quarter	2				
	Remaining unresolved at the end of the quarter	NIL				

**Notes :**

- 1 The above results, which includes audited results of the Subsidiary, have been duly audited by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website [www.alembic-india.com](http://www.alembic-india.com).
- 2 The Board has recommended dividend on Equity Shares at ₹ 1.40 per share i.e. 70% for the year ended on 31.03.2012 (PY ₹ 1/- per share i.e 50%)
- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

**For Alembic Pharmaceuticals Limited**

Place : Vadodara  
Date : 25th April, 2012

**Chirayu Amin**  
**Chairman and Managing Director**

**Visit us at [www.alembic-india.com](http://www.alembic-india.com)**

## Standalone Statement of Assets and Liabilities

₹ in lacs

Particulars	As at 31st March, 2012	As at 31st March, 2011
<b>A EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
(a) Share capital	3,770.32	3,770.32
(b) Reserves and surplus	32,315.92	23,850.64
<b>Sub-total - Shareholders' funds</b>	<b>36,086.24</b>	<b>27,620.96</b>
<b>2 Non-current liabilities</b>		
(a) Long-term borrowings	9,485.67	12,848.37
(b) Deferred tax liabilities (net)	952.90	537.46
(c) Other long-term liabilities	1,229.07	1,184.17
(d) Long-term provisions	539.04	510.16
<b>Sub-total - Non-current liabilities</b>	<b>12,206.69</b>	<b>15,080.16</b>
<b>3 Current liabilities</b>		
(a) Short-term borrowings	13,945.77	14,627.68
(b) Trade payables	18,192.75	13,175.41
(c) Other current liabilities	15,057.24	8,490.05
(d) Short-term provisions	3,566.34	2,590.85
<b>Sub-total - Current liabilities</b>	<b>50,762.10</b>	<b>38,883.99</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>99,055.02</b>	<b>81,585.11</b>
<b>B ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Fixed assets	32,605.83	29,848.84
(b) Non-current investments	335.42	335.42
(c) Long-term loans and advances	3,499.13	654.47
<b>Sub-total - Non-current assets</b>	<b>36,440.38</b>	<b>30,838.73</b>
<b>2 Current assets</b>		
(a) Inventories	25,874.15	21,923.19
(b) Trade receivables	18,683.28	20,197.39
(c) Cash and Bank Balance	2,572.47	128.80
(d) Short-term loans and advances	15,484.75	8,497.00
<b>Sub-total - Current assets</b>	<b>62,614.65</b>	<b>50,746.38</b>
<b>TOTAL - ASSETS</b>	<b>99,055.02</b>	<b>81,585.11</b>

For Alembic Pharmaceuticals Limited

Chirayu Amin  
Chairman and Managing Director